GIT1 and bladder transitional cell carcinoma: Scholars have reported that EZH2 can repress multiple downstream targets (e.g., KDM6A, GIT1) directly by binding to their promoter regions contributed to the progression of urothelial bladder carcinoma (Ler et al., 2017; Yang et al., 2020).